Impact of biologicals on health care

Home/Reports | Posted 25/10/2019 post-comment0 Post your comment

In a presentation entitled ‘Biosimilar Considerations for Real World Research and Stakeholder Questions’ delivered at the Drug Information Association’s (DIA) Biosimilars Conference, which was held on 23‒24 September 2019 in Bethesda, Maryland, USA, Dr Jaclyn Bosco of IQVIA discussed the impact that biologicals have had on health care.


Examples of the impact that biologicals have had on health care include:

Trastuzumab in human epidermal growth factor receptor 2 positive (HER-2+) breast cancer
Disease recurrences have halved and mortality has reduced by a third

Belimumab in lupus
First treatment advance in 50 years

β-interferons in multiple sclerosis
First disease-modifying therapy; fewer relapses and slowing of disability

Rituximab in non-Hodgkin’s lymphoma
New standard of care, increased survival

Anti-tumour necrosis factor-alpha (anti-TNF-α) in inflammatory bowel disease/Crohn’s disease
Revolutionized care: sustained remissions and reduced need for surgery

Targeted biological therapies in rheumatoid arthritis
Reduction in deformity and remission now a realistic goal

However, despite the great advantages of many biologicals, developing biosimilars of such complicated molecules is not always easy. In the following series of three articles the considerations for real-world research on biosimilars, uptake of biosimilars and the design of biosimilar studies are presented.

Related articles
Designing fit-for-purpose biosimilar studies

Uptake of biosimilars in different countries varies

Considerations for real-world research on biosimilars

1. Bosco J. Biosimilar considerations for real world research and stakeholder questions. DIA Biosimilars Conference; 2019 Sep 23‒24; Bethesda, Maryland, USA.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010